Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.
MHC
cancer
checkpoint blockade
immunotherapy
inhibitor
kinase
resistance
tumor escape
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
09 May 2019
09 May 2019
Historique:
received:
07
04
2019
revised:
06
05
2019
accepted:
07
05
2019
entrez:
12
5
2019
pubmed:
12
5
2019
medline:
4
9
2019
Statut:
epublish
Résumé
The interaction between programmed cell death protein (PD-1) and its ligand (PD-L1) is one of the main pathways used by some tumors to escape the immune response. In recent years, immunotherapies based on the use of antibodies against PD-1/PD-L1 have been postulated as a great promise for cancer treatment, increasing total survival compared to standard therapy in different tumors. Despite the hopefulness of these results, a significant percentage of patients do not respond to such therapy or will end up evolving toward a progressive disease. Besides their role in PD-L1 expression, altered protein kinases in tumor cells can limit the effectiveness of PD-1/PD-L1 blocking therapies at different levels. In this review, we describe the role of kinases that appear most frequently altered in tumor cells and that can be an impediment for the success of immunotherapies as well as the potential utility of protein kinase inhibitors to enhance the response to such treatments.
Identifiants
pubmed: 31075880
pii: ijms20092296
doi: 10.3390/ijms20092296
pmc: PMC6540309
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
Programmed Cell Death 1 Receptor
0
Protein Kinases
EC 2.7.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Thorac Oncol. 2018 Sep;13(9):1363-1372
pubmed: 29802888
Cancer J. 2018 Jan/Feb;24(1):47-53
pubmed: 29360728
Br J Clin Pharmacol. 2016 Oct;82(4):943-56
pubmed: 27232857
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Oncotarget. 2016 Nov 8;7(45):73242-73256
pubmed: 27689325
Clin Cancer Res. 2017 Aug 15;23(16):4534-4539
pubmed: 28611199
Drug Des Devel Ther. 2016 Aug 01;10:2443-59
pubmed: 27536065
Oncotarget. 2018 Sep 7;9(70):33290-33301
pubmed: 30279960
Methods Mol Biol. 2018;1856:247-254
pubmed: 30178256
J Immunol. 2008 Oct 1;181(7):4832-9
pubmed: 18802087
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
J Immunol. 2018 Jan 15;200(2):375-383
pubmed: 29311378
Med Oncol. 2013 Dec;30(4):754
pubmed: 24174317
J Biol Chem. 2015 May 1;290(18):11749-61
pubmed: 25795775
J Exp Med. 2019 Apr 1;216(4):982-1000
pubmed: 30872362
Drugs. 2018 Nov;78(17):1841-1846
pubmed: 30456447
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Cancer Immunol Immunother. 2009 Nov;58(11):1749-59
pubmed: 19551381
Nucleic Acids Res. 2009 Jan;37(Database issue):D593-7
pubmed: 18776214
Oncotarget. 2017 Apr 19;8(31):51936-51945
pubmed: 28881701
Clin Cancer Res. 2019 Feb 1;25(3):946-956
pubmed: 30297458
J Immunol. 2016 Mar 15;196(6):2431-7
pubmed: 26945088
Mod Pathol. 2019 Jan;32(1):147-153
pubmed: 30171197
Front Endocrinol (Lausanne). 2015 May 15;6:77
pubmed: 26029167
Mol Immunol. 2019 Sep;113:16-21
pubmed: 29224918
Cold Spring Harb Perspect Med. 2012 Dec 01;2(12):a006593
pubmed: 23209176
Ann Oncol. 2018 Mar 1;29(3):777-778
pubmed: 29161357
Int J Mol Sci. 2018 Dec 08;19(12):
pubmed: 30544835
J Immunother Cancer. 2018 Oct 22;6(1):109
pubmed: 30348216
Med Res Rev. 2014 Mar;34(2):280-300
pubmed: 23696246
J Thorac Oncol. 2019 May;14(5):933-939
pubmed: 30763730
Cells. 2018 Aug 23;7(9):
pubmed: 30142927
Immunol Rev. 2011 Sep;243(1):26-39
pubmed: 21884165
Cancers (Basel). 2019 Mar 27;11(4):
pubmed: 30934752
Semin Oncol. 2015 Aug;42(4):587-600
pubmed: 26320063
Cancer Immunol Res. 2016 Nov;4(11):936-947
pubmed: 27680026
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Oncotarget. 2016 Jul 19;7(29):44975-44990
pubmed: 27391444
J Biol Chem. 2015 Mar 27;290(13):8110-20
pubmed: 25645920
Signal Transduct Target Ther. 2018 Sep 28;3:26
pubmed: 30275987
Front Immunol. 2018 May 03;9:978
pubmed: 29774034
J Cell Biol. 2000 Oct 30;151(3):483-94
pubmed: 11062251
Acta Neuropathol. 2019 Feb;137(2):307-319
pubmed: 30584643
Eur J Cancer. 2017 Aug;81:116-129
pubmed: 28623775
J Biol Chem. 2007 Jul 13;282(28):20059-63
pubmed: 17502367
Mol Cell Biol. 1999 Aug;19(8):5800-10
pubmed: 10409766
Expert Rev Anticancer Ther. 2018 Sep;18(9):861-872
pubmed: 29936878
BMC Cancer. 2015 Apr 10;15:246
pubmed: 25884558
Front Immunol. 2016 Dec 12;7:550
pubmed: 28018338
Mol Cancer. 2018 Feb 19;17(1):48
pubmed: 29455673
Adv Cancer Res. 2002;85:145-74
pubmed: 12374285
Am J Cancer Res. 2018 Oct 01;8(10):2106-2115
pubmed: 30416860
Oncogene. 2007 May 14;26(22):3279-90
pubmed: 17496922
Genes Cancer. 2011 Dec;2(12):1097-105
pubmed: 22866201
J Cell Sci. 2004 Mar 15;117(Pt 8):1281-3
pubmed: 15020666
Apoptosis. 2018 Jun;23(5-6):265-289
pubmed: 29767378
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Histol Histopathol. 2018 Apr;33(4):379-388
pubmed: 28924970
J Cancer Res Clin Oncol. 2016 Aug;142(8):1775-80
pubmed: 27339628
Oncogene. 2017 Apr 20;36(16):2191-2201
pubmed: 27748764
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Trends Biochem Sci. 2014 Apr;39(4):183-90
pubmed: 24656806
Oncogene. 1998 May 14;16(19):2435-45
pubmed: 9627110
Ann N Y Acad Sci. 2010 Oct;1209:23-9
pubmed: 20958312
PLoS One. 2015 May 15;10(5):e0127092
pubmed: 25978653
Oncotarget. 2017 May 31;8(57):97671-97682
pubmed: 29228642
Cell Adh Migr. 2018;12(4):315-323
pubmed: 30187813
Int J Mol Sci. 2017 Nov 27;18(12):
pubmed: 29186886
Immunity. 2017 Feb 21;46(2):197-204
pubmed: 28228279
J Biol Chem. 2014 Aug 29;289(35):24238-49
pubmed: 25006253
Nat Commun. 2017 Jan 23;8:14124
pubmed: 28112156
Sci Rep. 2017 Mar 10;7:41779
pubmed: 28281545
Front Immunol. 2011 Oct 04;2:48
pubmed: 22566838
Cell Cycle. 2015;14(23):3661-2
pubmed: 26654768
JAMA Oncol. 2018 Feb 01;4(2):210-216
pubmed: 29270615
Front Immunol. 2018 Mar 27;9:578
pubmed: 29662490
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
Future Oncol. 2019 Sep 1;15(25):2915-2931
pubmed: 30793926
Lung Cancer. 2018 Jul;121:70-75
pubmed: 29858030
Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034
pubmed: 20066092
Genes Dev. 2006 Jul 1;20(13):1800-16
pubmed: 16818610
Oncol Rep. 2003 Nov-Dec;10(6):2005-8
pubmed: 14534734
Oncotarget. 2017 Nov 25;8(66):110693-110707
pubmed: 29299180
Mol Cell Biol. 1998 Jul;18(7):4131-40
pubmed: 9632797
Cell Biochem Funct. 2015 Jul;33(5):257-65
pubmed: 26153649
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Clin Cancer Res. 2017 Jun 1;23(11):2713-2722
pubmed: 28476872
Oncol Lett. 2018 Jan;15(1):41-47
pubmed: 29285186
Philos Trans R Soc Lond B Biol Sci. 1996 Feb 29;351(1336):127-34
pubmed: 8650258
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
J Cell Sci. 2005 Dec 15;118(Pt 24):5675-8
pubmed: 16339964
World J Gastroenterol. 2005 Jun 14;11(22):3385-91
pubmed: 15948243
Cancer Genet Cytogenet. 2005 Dec;163(2):123-9
pubmed: 16337854
Mol Cell Biol. 2002 Mar;22(6):1704-13
pubmed: 11865050
Drugs. 2017 Aug;77(12):1369-1376
pubmed: 28643244
Med Res Rev. 2011 Sep;31(5):794-818
pubmed: 20687158
Cancer Treat Rev. 2017 Jan;52:71-81
pubmed: 27951441
Oncotarget. 2014 Jul 30;5(14):5192-3
pubmed: 25114035
Cancer Manag Res. 2018 Oct 11;10:4501-4507
pubmed: 30349382
J Biol Chem. 2002 Jun 21;277(25):23037-43
pubmed: 11956217
Cancer Res. 2009 Feb 15;69(4):1668-77
pubmed: 19176400
Diabetologia. 2015 Dec;58(12):2819-31
pubmed: 26363783
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11381-6
pubmed: 21709260
Br J Pharmacol. 2017 Dec;174 Suppl 1:S225-S271
pubmed: 29055036
Genes Dev. 2010 Nov 15;24(22):2480-92
pubmed: 21078817
J Clin Invest. 2015 May;125(5):1780-9
pubmed: 25932675
Pharmacol Ther. 2003 May;98(2):129-42
pubmed: 12725866
Br J Pharmacol. 2014 Jan;171(1):24-37
pubmed: 24117156
Int J Cancer. 2009 Feb 1;124(3):511-5
pubmed: 19003982
Sci Rep. 2019 Mar 6;9(1):3705
pubmed: 30842489